Breast Cancer Clinical Practice Recommendations

Journal of Oncology Medicine & Practice

ISSN: 2576-3857

Open Access

Editorial - (2022) Volume 7, Issue 2

Breast Cancer Clinical Practice Recommendations

Zhao Yang*
*Correspondence: Zhao Yang, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, P.R. China, Email:
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, P.R. China

Received: 06-Apr-2022, Manuscript No. jomp-22-70432; Editor assigned: 09-Apr-2022, Pre QC No. p-70432; Reviewed: 20-Apr-2022, QC No. Q-70432; Revised: 24-Apr-2022, Manuscript No. R-70432; Published: 30-Apr-2022 , DOI: 10.37421/2157-7145.2022.7.157
Citation: Yang, Zhao. “Breast Cancer Clinical Practice Recommendations.” J Oncol Med & Pract 7 (2022): 157.
Copyright: © 2022 Yang J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


There are numerous clinical practise guidelines (cpgs) available for breast cancer screening and care. Here, we examine the advantages and disadvantages of cpgs from different professional associations and consensus groups in terms of the methodological quality, suggestions, and practicability. Guidelines from four groups were examined in relation to two clinical scenarios: the use of sentinel lymph node biopsy (slnb) following neoadjuvant chemotherapy (nac) for locally advanced bca, and adjuvant ovarian function suppression (ofs) in premenopausal women with earlystage oestrogen receptor-positive bca. Two impartial reviewers looked over the recommendations from the American Society of Clinical Oncology (asco), Cancer Care Ontario's Program in Evidence-Based Care (cco's pebc), the National Comprehensive Cancer Network of the United States (nccn), and the St. Gallen International Breast Cancer Consensus Conference. The agree ii instrument was used to assess the applicability and methodology of the guidelines. The guidelines created by asco and cco's pebc had the highest quality cpgs. It was discovered that the nccn and St. Gallen recommendations received lower marks for methodologic rigour. All recommendations received low applicability ratings [1]. Three of the recommendations for ofs were comparable. Contradictory recommendations for using slnb after nac were made by the various organisations.

Although the treatment of breast cancer has significantly improved over the past few decades, future developments in detection and therapy rely on the integration of genomes and precision medicine into clinical practise [2]. The fundamentals of genomics, breast cancer biomarkers and subtypes, and the implications of genomic discoveries for future breast cancer detection, therapy, and survival are covered in this article. The paper also discusses difficulties in implementing precision medicine in cancer care and the function of imaging in the detection and management of breast cancer in precision medicine. Breast cancer is the second-leading cause of cancer-related death in women and is the malignancy in which women are most frequently diagnosed [3]. Evidence from the literature demonstrates how important recent and ongoing research is to enhancing the clinical prognosis of breast cancer. This has been ascribed to advancements in breast cancer management techniques for screening, diagnosis, and treatment. But TNBC's dismal prognosis and medication resistance create significant barriers that are also today's challenges for controlling the disease. Similar to this, the incidence and mortality rates of breast cancer are on the rise among people in developing nations. Breast cancer remains a serious health breast cancer is clearly the top cause of cancer-related fatalities in women under the age of 45. The basic characteristics of this form of cancer appear to be potentially aggressive and highly heterogeneous [4].

However, management tactics, suggestions, and choices are not based on age, and the "complex" biology of this particular cancer kind is still unknown and understudied. The most frequent disease in women is breast cancer, and among the more than 14 million cancer survivors in the US, over one-fourth had a diagnosis of breast cancer. We have learnt a lot about the heterogeneity of breast cancer through several decades of basic and clinical trials research, and we have developed a sophisticated and interdisciplinary treatment strategy for the condition. The long-term and late effects of breast cancer treatment are gaining more attention, and this volume focuses mostly on them. The writers briefly summarise the topics of the succeeding chapters in this chapter before introducing the subject of breast cancer survivorship and highlighting the volume's structure and substance. There is a significant unmet need for metaplastic breast carcinomas (MPBC), which are uncommon, aggressive, and generally chemorefractory tumours.

The most common somatic mutations in TP53, PIK3CA, and PTEN are found in MPBCs, which are genetically diverse and may be amenable to innovative targeted therapeutics, according to recent research. Additionally, these tumours have been linked to tumor-infiltrating lymphocytes and overexpressed PD-L1, which indicates an endogenous immune response and supports the use of immunotherapies as a form of treatment [5]. Here, we concentrate on therapeutic possibilities for this challenging subtype of breast cancer, and we urge doctors to take targeted medicines and immunotherapies into account as a part of ongoing clinical trials. The majority of cases of malignancy in women are breast cancer. The average age is 64. The prognosis depends on the stage of the diagnosis and biological characteristics. Early breast cancer, locally progressed illness, and locoregional recurrence patients can all be cured. Multimodal therapy is common today. Surgery, radiation, and medication therapy are all part of it. Palliative care is used to treat patients with metastatic disease. Goals include symptom relief and extending survival. Over the past ten years, mortality from breast cancer has steadily declined. In Germany, the five-year rate of survival is 87%. Even more patients with patients with breast cancer have a possibility of recovery.

Conflicts of Interest



  1. Miller, Todd W., Brent N. Rexer, Joan T. Garrett and Carlos L. Arteaga. “Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer.” Breast Cancer Res 13 (2011)1-12.
  2. Google Scholar, Crossref, Indexed at

  3. Boyd, Norman F., Lisa J. Martin, Martin J. Yaffe, and Salomon Minkin. “Mammographic density and breast cancer risk: current understanding and future prospects.” Breast Cancer Res 13 (2011)1-12.
  4. Google Scholar, Crossref, Indexed at

  5. Place, Andrew E., Sung Jin Huh and Kornelia Polyak. “The microenvironment in breast cancer progression: biology and implications for treatment.” Breast Cancer Res 13 (2011): 1-11. 
  6. Google Scholar, Crossref, Indexed at

  7. Drasin, David J., Tyler P. Robin and Heide L. Ford. “Breast cancer epithelial-to-mesenchymal transition: Examining the functional consequences of plasticity.” Breast Cancer Res 13 (2011): 1-13.
  8. Google Scholar, Crossref, Indexed at

  9. Huang, Yi, Shweta Nayak, Rachel Jankowitz and Nancy E. Davidson. “Epigenetics in breast cancer: What's new?” Breast Cancer Res 13 (2011): 1-11.
  10. Google Scholar, Crossref, Indexed at

arrow_upward arrow_upward